Therefore, if we select small molecule compounds that block RGS16’s binding to the TRAF6/TAB2 complex by screening the library of natural or synthetic small molecule compounds, we can develop novel potential therapies for CRC through targeting RGS16. This evidence concerns the gene TAB2 and colorectal carcinoma.